Genentech’s Cancer Product Line Expands, As Do Its Post-Market Manufacturing Obligations
This article was originally published in RPM Report
Genentech appears to be having significant manufacturing problems for some of its new cancer therapies. FDA hasn’t taken enforcement action yet, but the agency has delayed two approvals and tied them to post-market requirements to address QC issues.
You may also be interested in...
FDA’s second wave of Breakthrough Therapies will look markedly different from the initial flurry of approvals. After an early focus on oncology, FDA is reviewing a more diverse set of applications in the antiviral, vaccines and cardiovascular arenas. And there will be more “breaks” during development as sponsors start to request designations based on earlier data. What will Breakthrough look like in the third year of the program?
The Energy & Commerce Committee “21st Century Cures” Process promises to set a pro-innovation tone heading into the next user fee reauthorization cycle. There is one theme, however, that may be perilous for industry moving forward: Expanded Access.
The complex manufacturing required by Genentech’s antibody-drug conjugate trastuzumab emtansine pushed FDA’s review two months past the agency’s internal action timetable, required four review teams from three CDER offices and produced a veritable blizzard of information requests. But is that level of intensity sustainable as the expanding ADC pipeline matures?